In brief
- Eli Lilly announces the acquisition of AtaiBeckley for up to $3.8 billion, the largest psychedelic deal in history
- The lead asset is BPL-003, a synthetic 5-MeO-DMT nasal spray currently in phase 3 for treatment-resistant depression
- The pipeline also includes VLS-01, a DMT buccal film, and EMP-01, an MDMA-derived candidate for social anxiety
One of the world’s largest pharmaceutical companies just put a price tag on a synthetic derivative of 5-MeO-DMT. On July 16, Eli Lilly announced a definitive agreement to acquire AtaiBeckley, the biopharmaceutical company developing therapies based on 5-MeO-DMT and DMT for mental health conditions. It marks the largest transaction ever closed in the psychedelic space, confirming that Big Pharma’s interest in these molecules is no longer a fringe experiment.
A figure you don’t see every day
According to the joint press release from both companies, Lilly will pay $6.75 per share in cash, roughly $2.8 billion in total, representing a premium of nearly 40% over AtaiBeckley’s average trading price during the prior 30 days. On top of that, there is a contingent value right (CVR) of up to $2.50 per share, approximately $1 billion more, payable only if three specific milestones are met: $1.00 when VLS-01 enters phase 3, $0.50 when BPL-003 secures FDA approval and DEA rescheduling, and another $1.00 when VLS-01 achieves both. In total, the deal could reach $3.8 billion. Lilly did not attach any financing conditions to the agreement, which it expects to close in the third quarter of this year following approval by AtaiBeckley shareholders.
What exactly is BPL-003
The asset of greatest interest to Lilly is BPL-003, scientifically known as mebufotenin benzoate: a synthetic formulation of 5-MeO-DMT administered intranasally during a single clinical visit lasting around two hours. It has already received Breakthrough Therapy designation from the US FDA and completed phase 2b trials, where results showed rapid reductions in depressive symptoms that persisted for months following a single dose. Backed by those findings, the drug has advanced to phase 3, the final hurdle before potential regulatory approval. AtaiBeckley’s pipeline does not end there: it also includes VLS-01, a DMT buccal film targeting treatment-resistant depression in phase 2b, and EMP-01, a form of MDMA designed for social anxiety disorder, currently in phase 2.
What this means
The fact that a titan like Lilly is spending billions on a molecule that remains illegal outside clinical trials in most countries speaks volumes about where the sector is headed. The acquisition will not change the legal status of 5-MeO-DMT or DMT overnight: part of the payout depends precisely on the DEA rescheduling these compounds if the FDA ultimately approves them as medicines. This is a business transaction, not a completed regulatory overhaul, and it should be interpreted with appropriate caution. Yet for those who have spent years documenting the therapeutic potential of these molecules, seeing conventional pharma wager billions on them is a signal hard to overlook, even if the road to an approved, accessible drug remains long.
Source
- Eli Lilly and Company / AtaiBeckley Inc. Lilly to Acquire AtaiBeckley to Advance Therapies for Treatment-Resistant Depression and Other Mental Health Conditions. PR Newswire, July 16, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
